Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

Inclusion Criteria

• •Histologically confirmed CD20 positive (+) follicular lymphoma, grade 1, 2, or 3a，bulky disease (Mass diameter ≥ 7 cm)
• •Have had no prior systemic treatment for lymphoma
• •Meeting Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria for initiation of treatment
• •Age 18-75 years
• •ECOG Performance Status of 0-2 .Stage II, III, or IV by Ann Arbor staging system.
• •Demonstrate adequate organ function as defined below; all screening labs to be obtained within 28 days prior to registration.
• •1. Hematological: WBC≥3.5×109/L, Platelets ≥ 75×109/L,Absolute Neutrophil Count (ANC) ≥ 1.0×109/L，Hemoglobin (Hgb) ≥ 80 g/L
• •2. Renal: Calculated creatinine clearance ≥ 50 mL/min
• •3. Hepatic: Bilirubin ≤ 1.5 × upper limit of normal (ULN), AST/ALT ≤ 2.5×ULN
• •Females of childbearing potential must be willing to abstain from vaginal intercourse or use an effective method(s) of contraception from the time of informed consent, during the study and for 6 months after the last dose of study drug(s). Males able to father a child must be willing to abstain
• •Life expectancy ≥6 months
• •Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study